2022 / 01

Next Paper
DOI: 10.24075/brsmu.2022.007

ORIGINAL RESEARCH

Dynamic changes in the concentration of anti-SARS-CoV-2 antibodies within 12 months after recovery from COVID-19

Mayanskiy NA1, Brzhozovskaya EA1, Stoyanova SS1, Frolkov AV1, Lebedin YuS2
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 XEMA LLC, Moscow, Russia

Correspondence should be addressed: Nikolay A. Mayanskiy
Ostrovitianova, 1, Moscow, Russia; moc.liamg@yalokin.yiksnayam

About paper

Author contribution: Mayansky NA — concept, data processing, manuscript writing; Brzhozovskaya EA — sample collection, ELISA, data processing, making illustrations; Stoyanova SS — sample collection, data processing, making illustrations; Frolkov AV — data processing, manuscript preparation; Lebedin YuS — concept, ELISA, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Pirogov Russian National Research Medical University (protocol № 197 dated May 21, 2020).

Received: 2022-02-01 Accepted: 2022-02-14 Published online: 2022-02-20
|
  1. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021; 397: 1347–8. DOI: 10.1016/ S0140-6736(21)00527-4.
  2. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021; 595: 426–31. DOI: 10.1038/s41586-021-03696-9.
  3. De Giorgi V, West KA, Henning AN, Chen LN, Holbrook MR, Gross R, et al. Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection. J Infect Dis. 2021: jiab295. DOI: 10.1093/infdis/jiab295.
  4. SARS-CoV-2-IgG EIA instruction manual. https://xema-medica. com/eng/sets/ifu/Archive/. (kit K153GQIE v2018). (Assessed 20 September 2021).
  5. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody responses up to 13 months after SARSCoV-2 infection and risk of reinfection. EBioMedicine. 2021; 71: 103561. DOI: 10.1016/j.ebiom.2021.103561.
  6. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021; 398: 121–30. DOI: 10.1016/S01406736(21)01420-3.
  7. Kim Y, Lee JH, Ko GY, Ryu JH, Jang JH, Bae H, et al. Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test. Diagnostics (Basel). 2021; 11: 1496. DOI: 10.3390/diagnostics11081496.